However, no association was found between BMI and survival. Studies aimed at elucidating the mechanisms linking a high BMI to less aggressive clinicopathological features in patients with EC are further warranted.

Disclosures None.

#505 CORRELATION OF MICROSATELLITE INSTABILITY WITH PATHOLOGY FEATURES OF ENDOMETRIAL CANCER PATIENTS
10.1136/ijgc-2023-ESGO.339

Introduction/Background Molecular classification of endometrial cancer is the standard of referencing for early stage disease and takes precedence over standard pathology concerning the decision to proceed with adjuvant treatment. Several studies evaluated its impact on survival outcomes of endometrial cancer patients and in the present prospective cohort we evaluate the correlation of microsatellite instability (MSI) with standard pathology features of the disease.

Methodology The study is based in a consecutive cohort of patients. All the pathological features were retrieved and an analysis of microsatellite instability was performed with the assessment of MLH1, PMS2, MSH2 and MSH6. Correlation analysis was performed concerning the size of tumor, depth of myometrial invasion, distance from myometrial serosa, stage of disease and presence of lymphovascular space invasion.

Results Overall, 66 patients were retrieved of whom 47 (71%) presented with early-stage disease and 19 (29%) had advanced stage disease. Mean patient age was 62 years (37–83). Microsatellite instability was observed in 23 patients (34.8%). Neither tumor volume, nor the depth of myometrial invasion correlated with the presence of MSI. Positive lymph nodes and lymphovascular space invasion were significantly more prevalent in patients with MSI (p=.016, p=.042). Omental metastases did not differ among the two groups.

Conclusion Microsatellite instability is associated with lymphovascular space invasion and lymph node metastases. These findings explain the increased recurrence rates and decreased overall survival observed by other researchers and should be taken into account during the preoperative assessment and postoperative follow-up of patients.

Disclosures No conflicts of interest. The present study was not funded.

#508 PERITONEAL WASHINGS IN PRESUMED LOW GRADE EARLY-STAGE ENDOMETRIAL CANCER: DOES IT CHANGE OUR MANAGEMENT?
1Holly Pearson, 1Anna Forbes, 2Tineke Vergeldt*. 1School of Medicine Newcastle University, Newcastle Upon Tyne, UK; 2Northern Gynaecological Oncology Centre, Gateshead, UK
10.1136/ijgc-2023-ESGO.340

Introduction/Background In the International Federation of Obstetrics and Gynaecology (FIGO) staging for endometrial cancer developed in 1988 positive peritoneal washings were regarded as FIGO stage 3A. The revised 2009 FIGO staging no longer includes peritoneal cytology in the staging of the cancer.

The aim of this retrospective study was to assess how often peritoneal washings show positive cytology in presumed low grade early-stage endometrial cancer and whether this influenced the advice for adjuvant treatment in our region.

Methodology An observational retrospective analysis was performed of all patients identified to have presumed FIGO (2009) stage 1 grade 1 or 2 endometrial cancer preoperatively in 2020 and 2021 who were discussed in the multi-disciplinary team (MDT) meetings at the Northern Gynaecological Oncology Centre in the United Kingdom, and who were surgically managed with a total hysterectomy and bilateral salpingo-oophorectomy. Patients were identified by conducting a search in the database used for the MDT discussions. For confirmation the pathology records from all these patients were screened. The MDT discussions of all patients with positive peritoneal washings were reviewed in order to determine the recommendation for adjuvant treatment they were offered. This was compared with the British Gynaecological Cancer Society guideline, to determine if management was impacted by peritoneal washings.

Results The search identified 260 patients with presumed low grade early-stage endometrial cancer who had undergone surgery for their cancer, of which 20 patients (7.7%) had positive peritoneal washings. Patients with positive peritoneal washings more often had a higher preoperative and postoperative grade, a higher final FIGO stage and more often lymphovascular space invasion. The positive peritoneal washings did not influence the MDT recommendation on adjuvant treatment.

Conclusion The presence of positive peritoneal washings didn’t influence further management. The prognostic value of positive peritoneal washings in endometrial cancer is still a topic of debate in literature.

Disclosures None.

#521 EFFECTIVENESS OF MEGESTROL FOR THE TREATMENT OF PATIENTS WITH ATYPICAL ENDOMETRIAL HYPERPLASIA OR ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA (STAGE IA, WELL DIFFERENTIATED)
1Setareh Akhavan*, 2Fahimeh Sabet, 3Azamsadat Mousavi, 2Shahruzad Sheikh Hasani. 1Tehran university of medical sciences, Tehran, Iran; 2Isfahan university of medical sciences, Isfahan, Iran
10.1136/ijgc-2023-ESGO.341

Introduction/Background We aimed to evaluate treatment responses and recurrence rate of atypical endometrial hyperplasia (AEH) and endometrial endometrioid adenocarcinoma (EA) with Stage IA Grade 1 to megestrol in Iranian patients who are candidates for medical treatments.

Methodology In a retrospective cohort study that was conducted on 50 patients with AEH and 22 patients with EA who were referred to the oncology clinic of Imam Khomeini Hospital, Tehran, Iran, during 2006–2016, we recruited all patients with AEH or EA of Stage IA Grade 1 and their disease was diagnosed during endometrial curettage with or without hysteroscopy. Patients were initially treated with 160 mg of megestrol daily, along with aspirin up to 3 months, and then after 3–4 weeks of discharge of the drugs, patients underwent curettage with hysteroscopy.